A Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for Bococizumab, a Humanized Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, and Its Application in Early Clinical Development-Reference-Cited by-同舟云学术

A Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for Bococizumab, a Humanized Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, and Its Application in Early Clinical Development

Published:2017-02-09 Issue:7 Volume:57 Page:855-864
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Udata Chandrasekhar¹,Garzone Pamela D.¹,Gumbiner Barry¹,Joh Tenshang¹,Liang Hong¹,Liao Kai-Hsin¹,Williams Jason H.¹,Meng Xu¹

Affiliation:

1. World Wide Research and Development; Pfizer Inc; San Diego California

Funder

Pfizer

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference24 articles.

1. Trends in age-specific coronary heart disease mortality in the European Union over three decades: 1980-2009;Nichols;Eur Heart J.,2013

2. Executive summary: heart disease and stroke statistics-2014 update: a report from the American Heart Association;Go;Circulation.,2014

3. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal;JH;J Am Coll Cardiol.,2004

4. Lipid lowering with PCSK9 inhibitors;Dadu;Nat Rev Cardiol.,2014

5. Residual macrovascular risk in 2013: what have we learned;Fruchart;Cardiovasc Diabetol.,2014

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modeling the subcutaneous pharmacokinetics of antibodies co‐administered with rHuPH20;Clinical and Translational Science;2024-04

2. Implications of Immunogenicity Testing for Therapeutic Monoclonal Antibodies: A Quantitative Pharmacology Framework;The AAPS Journal;2024-03-07

3. Population PK/PD modeling of low‐density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti‐PCSK9 monoclonal antibody;CPT: Pharmacometrics & Systems Pharmacology;2023-11-22

4. Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects;Int. Journal of Clinical Pharmacology and Therapeutics;2019-12-01

5. Molecular Characterization of Familial Hypercholesterolemia in a North American Cohort;Journal of the Endocrine Society;2019-11-29